This material was presented in the 25th European Congress of Psychiatry which was organised by the European Psychiatry Association in Florence, Italy from 1-4th April 2017. I had access to the material as I attended the full Congress. Please note that this material remains the intellectual property of the European Psychiatry Association and its authors and any citation should include a full reference to it. For more information on the EPA and how to become a member, please visit: http://www.europsy.net/

1. Is the use of long-acting injectable antipsychotic
extended in the outpatient treatment of bipolar
disorder? A brief description
Ll. Niell 1, G. Montero 1R.A. Baena 1, Í. Alberdi 1, M. M. Tenorio 1, A. Carrillo 2
1 Hospital Clínico San Carlos, Madrid
2CSM Latina, Madrid
Aims
Obtain and analyze information on treatment
guidelines, with particular emphasis on the
use of antipsychotics, in patients diagnosed
with Bipolar Disorder I and Bipolar Disorder II
who are treated at a mental health center in a
district of Madrid (Spain) under the conditions
of habitual clinical practice.
Then, compare with recently published
literature.
Results
94% of patients are taking mood stabilizer
treatment (68% lithium, 24% valproate, 1% and
1% Carbamazepine and Lamotrigine). 4% take
lithium and valproate in combination. 48% of
patients are taking some antipsychotic
(atypical about 90%). Of these, only 10% in
injectable form, and 5% take both oral and
injectable antipsychotics.
Conclusions
T h e d i m i n i s h e d u s e o f i n j e c t a b l e
antipsychotics, well below recent publications,
draws the attention. You can probably explain
this low proportion of injectable medication
because we are generally dealing with stable
patients with a long-term disorder.
Methods
We performed a descriptive study of a sample
of 100 patients diagnosed with bipolar
disorder (type I and type II) at any stage of the
disease who receive regular treatment in a
mental health center in a district of Madrid.
Information regarding the treatment used,
especially the use of antipsychotics (either in
a single teraphy or in combination with other
d r u g s s u c h a s m o o d s t a b i l i z e r s ,
antidepressants, hypnotics or anxiolytics), was
collected retrospectively from the data
obtained from the medical record.
Data sociodemographic, clinical and evolutionary (n=
100)
DIAGNOSIS
TB I 70%
TB II 30%
AVERAGE 55,3
GENDER
Man 35%
Woman 65%
LABOR SITUATION
Active 30%
Unemployed 10%
Their work 20%
Inability to work 20%
Retired 17%
AVERAGE OF YEARS OF EVOLUTION 22.8
AVERAGE EPISODES 5,3
BASELINE
Euthymia 80%
Episode depressed 8%
Episode manic 2%
Other 10%
Use of antipsychotic
35%
45%
7%
14%
Injectable Oral and Injectable
Oral No antipsychotic
Use of mood stabilizers
4%1%1%
23%
65%
6%
No mood stabilizer
Lithium
Valproate
Carbamazepine
Lamotrigine
(Lithium and Valproate)